Adalimumab induced interstitial lung disease
نویسندگان
چکیده
منابع مشابه
Drug Induced Interstitial Lung Disease
With an increasing number of therapeutic drugs, the list of drugs that is responsible for severe pulmonary disease also grows. Many drugs have been associated with pulmonary complications of various types, including interstitial inflammation and fibrosis, bronchospasm, pulmonary edema, and pleural effusions. Drug-induced interstitial lung disease (DILD) can be caused by chemotherapeutic agents,...
متن کاملTimolol-induced interstitial lung disease
Timolol maleate is a non-selective beta-adrenergic receptor blocking agent with demonstrated efficacy in the treatment of open-angle glaucoma. A 76 year old female who presented with productive cough, progressive dyspnea and hypoxia after starting timolol maleate opthalamic drops following glaucoma surgery. The patient was diagnosed with interstitial lung disease secondary to timolol treatment ...
متن کاملAdalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis*
The use of immunobiological agents for the treatment of autoimmune diseases is increasing in medical practice. Anti-TNF therapies have been increasingly used in refractory autoimmune diseases, especially rheumatoid arthritis, with promising results. However, the use of such therapies has been associated with an increased risk of developing other autoimmune diseases. In addition, the use of anti...
متن کاملInfluenza vaccine-induced interstitial lung disease.
typing identifies evidence for recombination and two distinct lineages of Corynebacterium diphtheriae. J Clin Microbiol 2010; 48: 4177– 4185. 3 Wagner KS, White JM, Lucenko I, et al. Diphtheria in the postepidemic period, Europe, 2000–2009. Emerg Infect Dis 2012; 18: 217–225. 4 Wilson AP. The return of Corynebacterium diphtheriae: the rise of nontoxigenic strains. J Hosp Infect 1995; 30: Suppl....
متن کاملRecurrent gefitinib-induced interstitial lung disease.
Gefitinib, the epidermal growth factor receptor tyrosine kinase inhibitor, is effective for patients with non-small cell lung cancer. However, a serious adverse effect, interstitial lung disease (ILD), has been reported. The re-administration of gefitinib might be considered when there is no other choice of treatment and a therapeutic effect can be expected; however, there is no published data ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Respiratory Medicine Case Reports
سال: 2020
ISSN: 2213-0071
DOI: 10.1016/j.rmcr.2020.101012